Use of Ber-EP4 and Epithelial Specific Antigen to Differentiate Clinical Simulators of Basal Cell Carcinoma
Open Access
- 1 January 2013
- journal article
- Published by SAGE Publications in Biomarkers in Cancer
- Vol. 5 (5) , BIC.S11856-11
- https://doi.org/10.4137/bic.s11856
Abstract
EpCam is a transmembrane epithelial adhesion molecule present on all non-squamous epithelial cells. It is often overexpressed in certain carcinomas, such as breast and colon, and in dermatology, eg, basal cell carcinoma (BCC). Various monoclonal antibodies have been used to detect EpCam, including BerEP4 and epithelial specific antigen. We compared anti-EpCam clones, BerEP4, and epithelial specific antigen clone VU-1D9. One hundred and twelve lesions were stained with both antibodies. All basal cell carcinomas stained uniformly and strongly positive with both antibodies. Diffuse positive staining was also seen in all trichoepitheliomas and merkel cell carcinomas. Focal positive staining was seen in squamous cell carcinoma and benign sebaceous neoplasms. Clone VU-1D9 was more likely to produce focal positive staining as compared to BerEP4. This focal positive staining of sebaceous neoplasms and squamous cell carcinomas is a potential diagnostic pitfall.Keywords
This publication has 23 references indexed in Scilit:
- Documenting the Natural History of Patients With Resected Stage II Adenocarcinoma of the Colon After Random Assignment to Adjuvant Treatment With Edrecolomab or Observation: Results From CALGB 9581Journal of Clinical Oncology, 2011
- Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodiesCancer Cell International, 2010
- An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancerAnnals of Oncology, 2010
- Adjuvant Therapy With the Monoclonal Antibody Edrecolomab Plus Fluorouracil-Based Therapy Does Not Improve Overall Survival of Patients With Stage III Colon CancerJournal of Clinical Oncology, 2009
- Nuclear signalling by tumour-associated antigen EpCAMNature Cell Biology, 2009
- EpCAM (CD326) finding its role in cancerBritish Journal of Cancer, 2007
- Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancersBritish Journal of Cancer, 2006
- Frequent EpCam protein expression in human carcinomasPublished by Elsevier ,2004
- Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised studyThe Lancet, 2002
- Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial.Journal of Clinical Pathology, 1990